Roflumilast Cream, 0.15% Boosts AD Patients QofL With Spillover Benefits Seen for Families, Caregivers
Roflumilast cream 0.15% (Zoryve, Arcutis) rapidly decreases the impact of atopic dermatitis (AD), including sleep loss and daily activities, on patients, families, and caregivers, according to data presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, MA. Roflumilast cream 0.15% also resulted in significant improvements across all efficacy endpoints, […]